

IN THE CLAIMS

Please add the following claims:

28. (New) A method of preparing a composition for stimulating CTL activity against human immunodeficiency virus, comprising

(a) introducing into a vector DNA or liposome a nucleic acid encoding an envelope glycoprotein of HIV, wherein said envelope glycoprotein comprises a deletion of the third variable loop (V3); and

(b) mixing said vector DNA or liposome with a suitable adjuvant.

29. (New) The method of Claim 28, wherein said nucleic acid is introduced into antigen presenting cells (APCs) and said APCs are mixed with adjuvant.

30. (New) The method of Claim 28, wherein said deletion of the third variable loop (V3) comprises deletion of amino acids 297 to 329 in said variable loop.

31. (New) The method of Claim 28, wherein said human immunodeficiency virus is human immunodeficiency virus 1 IIIB.

32. (New) A method of stimulating a CTL response in a patient, comprising administering the composition prepared according to the method of Claim 28 to the patient in an amount sufficient to stimulate a CTL response.

33. (New) A method of stimulating a CTL response in a patient, comprising administering the composition prepared according to the method of Claim 29 to the patient in an amount sufficient to stimulate a CTL response.

34. (New) A method of stimulating a CTL response in a patient, comprising administering the composition prepared according to the method of Claim 30 to the patient in an amount sufficient to stimulate a CTL response.

35. (New) A method of stimulating a CTL response in a patient, comprising

administering the composition prepared according to the method of Claim 31 to the patient in an amount sufficient to stimulate a CTL response.

*Patent*  
36. (New) A method of stimulating a CTL response in a patient, comprising  
administering the composition prepared according to the method of Claim 32 to the patient in an amount sufficient to stimulate a CTL response.

---